TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06156345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conservative with Denneroll
Description: Denneroll cervical traction orthodontic traction for 3 to 15 minutes once daily with conservative management of stretching and relaxation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative
Description: conservative management of stretching and relaxation with placebo traction.
Study: NCT06412263

Intervention type: PROCEDURE
Intervention: Routine root canal treatment/ retreatment
Description: It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment

Intervention type: PROCEDURE
Intervention: Routine root canal treatment/ retreatment
Description: It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment

Intervention type: PROCEDURE
Intervention: Routine root canal treatment/ retreatment
Description: It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment

Intervention type: PROCEDURE
Intervention: Routine root canal treatment/ retreatment
Description: It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment
Study: NCT06303973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOE
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PNG
Description: In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study: NCT06520449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NTA-476
Description: The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.
Study: NCT05878470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
Study: NCT05655975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: upper gi endoscopy
Description: In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: upper gi endoscopy
Description: In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
Study: NCT06014307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet order: PBMA, Animal
Description: Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet order: PBMA, Animal
Description: Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet order: Animal, PBMA
Description: Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet order: Animal, PBMA
Description: Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.
Study: NCT04032925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICSO
Description: PICSO therapy is delivered through the PICSO Impulse System, which consists of the PICSO Impulse console and PICSO impulse catheter. The PICSO therapy is delivered in each patient for a minimum of 20 minutes to a maximum of 45 minutes.~The PICSO Impulse catheter is automatically activated by the PICSO Impulse console. It is inserted in the coronary sinus via femoral vein access. The PICSO Impulse Console cyclically inflates and deflates the balloon at the tip of the PICSO Impulse catheter, generating transient increase in coronary sinus pressure.
Study: NCT05144672

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory tests
Description: Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin.

Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI

Intervention type: PROCEDURE
Intervention: Electrocardiogram and Fundus examination
Description: Fundus examination by direct ophthalmoscope

Intervention type: OTHER
Intervention: Estimated glomerular filtration rate (eGFR)
Description: Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.

Intervention type: OTHER
Intervention: Brachial index
Description: The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory tests
Description: Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).

Intervention type: RADIATION
Intervention: Abdominal ultrasound.
Description: It will be performed for patients only.
Study: NCT05827705

Intervention type: OTHER
Intervention: need for Ephedrine hydrochloride
Description: ephedrine dose in hypotension
Study: NCT06028698

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inducing positive emotion music
Description: listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inducing positive emotion music
Description: listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inducing positive emotion music
Description: listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
Study: NCT04729348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Oral, daily, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral, daily, dosage per protocol
Study: NCT05778994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTORUS
Description: Exercise protocol with intorus
Study: NCT05953298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT)
Description: Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
Study: NCT05243628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afrezza (insulin human) Inhalation Powder
Description: Pharmaceutical form: powder~Route of administration: inhalation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afrezza (insulin human) Inhalation Powder
Description: Pharmaceutical form: powder~Route of administration: inhalation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Description: Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Description: Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
Study: NCT05726331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic Care
Description: Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
Study: NCT06400862

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: eOCT implantation
Description: eOCT is regarded as an Advanced Therapy Product (ATP).
Study: NCT05262127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flash Version of EMDR
Description: EMDR and the inclusion of a positive engaging focus generated autonomously by participant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flash Version of EMDR
Description: EMDR and the inclusion of a positive engaging focus generated autonomously by participant
Study: NCT05726331

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
Study: NCT04982705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Part 1.1] IDG-16177
Description: \[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [Part 1.1] Placebo of IDG-16177
Description: \[Part 1.1\] subjects will receive a single oral dose of IMP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [Part 2] Sitagliptin
Description: Administration of Sitagliptin 100mg once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Part1.2] IDG-16177
Description: \[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Part 2] IDG-16177
Description: \[Part 2\] Administration once daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [Part 1.2] Placebo of IDG-16177
Description: \[Part 1.2\] Administration once daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [Part 2] Placebo of IDG-16177
Description: \[Part 2\] Administration once daily for 4 weeks.
Study: NCT04895930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: 80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
Study: NCT05096897

Intervention type: OTHER
Intervention: Self-administrated questionnaires
Description: GOHAI, IBD-Q, IBD-disk
Study: NCT05766436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo ODF and 0.9% normal saline nebulizer
Study: NCT06522477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality gait training
Description: Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality gait training
Description: Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.
Study: NCT05480839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-IBCS
Description: Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReLA-IBCS Early
Description: Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReLA-ISBCS
Description: Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
Study: NCT05432024

Intervention type: DEVICE
Intervention: Catheter ablation
Description: An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.

Intervention type: DEVICE
Intervention: Catheter ablation
Description: An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.

Intervention type: DEVICE
Intervention: Catheter ablation
Description: An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
Study: NCT06208683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mumps vaccine, Live (MV)
Description: 0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mumps vaccine, Live (MV)
Description: 0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mumps vaccine, Live (MV)
Description: 0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
Study: NCT05576766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: 1. Routine information provided before surgery.~2. No nutritional therapy.~3. No aerobic exercise.~4. No pelvic floor muscle training.~5. No psychiatrist intervention.~6. Bowel preparation with oral cathartic agent.~7. Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~8. Hypothermia prevention not emphasized.~9. General anesthesia; regional block not emphasized.~10. Routine blood pressure management.~11. Mobilization from postoperative day 1.~12. Start oral feeding from postoperative day 1.~13. Patient-controlled analgesia with opioids.~14. Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~15. Routine pelvic drainage tube removal (usually at postoperative day 4).~16. Routine urinary catheterization removal (usually at postoperative day 14).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS management pathway
Description: 1. Patient consultation and education before surgery.~2. Nutritional intervention for patients whose BMI\<18.5 or BMI\>24 kg/m2.~3. Aerobic exercise for 2 weeks before surgery.~4. Pelvic floor muscle training for 2 weeks before surgery.~5. Psychiatrist intervention for patients with severe depression and anxiety.~6. No bowel preparation before surgery.~7. Provide oral carbohydrate solution 2 hours before surgery.~8. Hypothermia prevention.~9. General anesthesia combined with regional block.~10. Goal-directed fluid infusion and targeted blood pressure management.~11. Early mobilization.~12. Early oral feeding.~13. Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~14. Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~15. Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~16. Early urinary catheterization removal (at postoperative day 7) unless contraindicated.
Study: NCT04278898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-acetylcysteine Single Dose 2700 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-acetylcysteine Single Dose 2700 mg taken orally
Study: NCT05238818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocyte Injection (GT202)
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. T cells then are manufactured to express mbIL-12. After lymphodepletion, patients are infused with GT202 followed by IL-2.
Study: NCT05252923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
Study: NCT04839536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalant product
Description: Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
Study: NCT06077331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10374 tablets 1mg
Description: Administered orally QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10374 tablets 1mg
Description: Administered orally QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10374 tablets 5mg
Description: Administered orally QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10374 tablets 5mg
Description: Administered orally QD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10374-matched placebo tablets
Description: Administered orally QD for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-10374-matched placebo tablets
Description: Administered orally QD for 12 weeks
Study: NCT06396702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EASE-SOT
Description: EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys) using electronic patient reported outcome measures (ePROMs). The intervention duration is 8 weeks. Based on individual preference, EASE-psy may be administered in person or virtually via Microsoft Teams. Based on individual preference, participants may receive ePROMs either on tablets or to their personal electronic devices via email, while at the hospital ward and in clinics, ensuring easy access and administration of these tools.